Mirati Therapeutics To Present At Upcoming Healthcare Conferences
- Cowen 39th Annual Healthcare Conference in
Bostonon Tuesday, March 12th at 11:20 a.m. ET/ 8:20 a.m. PT.
- Oppenheimer 29th Annual Healthcare Conference in
New Yorkon Tuesday, March 19th at 8:35 a.m. ET/ 5:35 a.m. PT.
The presentations will be webcast and made available through the "Investors" section of www.mirati.com, and replays will be made available for 90 days following the events.
Mirati is also developing novel inhibitors of KRAS mutations including MRTX849, a potent and selective inhibitor of KRAS G12C. This previously difficult to drug target drives approximately 14% of non-small cell lung adenocarcinomas, 4% of colorectal cancer as well as smaller percentages of several other difficult-to-treat cancers. MRTX849 is being evaluated in a Phase 1/2 clinical trial as a treatment for patients with KRAS G12C-positive tumors. Our research on G12C has led to breakthroughs in targeting other KRAS mutations including G12D which drives tumor growth in more patients than G12C and includes pancreatic, colorectal and other types of cancer.
View original content to download multimedia:http://www.prnewswire.com/news-releases/mirati-therapeutics-to-present-at-upcoming-healthcare-conferences-300807185.html
Temre Johnson, Mirati Therapeutics Inc., Director, Investor Relations & Corporate Communications, (858) 332-3562, firstname.lastname@example.org